France's defence minister said the budget deficit would exceed 6.5% of GDP in 2027 unless corrective measures are taken.

AstraZeneca will invest about 200 mln yuan to upgrade its Wuxi production and supply base with a new drug development and supply building to support process development and production for its cardiovascular drug candidates and to back global supply after commercialisation. The 5,800 sq m facility is scheduled to enter service in Q4 2029 and is expected to have annual capacity of about 400 mln tablets. Upon completion, the Wuxi site will engage in commercial-stage process development and could become AstraZeneca’s first APAC base capable of supporting a new drug’s global launch and supply.

Eurozone August CPI final MoM 0.4% (exp. 0.4%; prior 0.4%)